[Caihua News] Maibo Pharmaceutical-B (02181.HK) announced that China's State Drug Administration "NMPA" has approved the application of CMAB807X for clinical trials in the treatment of tumor bone metastasis.
CMAB807X (deschumab) is a kind of human IgG2 monoclonal antibody, which has affinity and specificity to human RANKL (nuclear factor κ-B ligand receptor activator). RANKL is a transmembrane or soluble protein, which is very important for the formation, function and survival of osteoclasts (cells responsible for bone resorption). CMAB807 can prevent RANKL from activating its receptor RANK on the surface of osteoclasts and their precursors. Preventing the interaction of RANKL/RANK can inhibit the formation, function and survival of osteoclasts, thus reduce bone resorption and increase the bone mass and strength of cortical bone and trabecular bone.
CMAB807 is currently conducting phase III clinical trials of osteoporosis. CMAB807X is a dosage form of CMAB807 for the treatment of tumor bone metastasis. After CMAB807X's new drug application is approved by NMPA, it is expected to be used to treat tumor bone metastasis and bone giant cell tumor, and to prevent bone metastasis of solid tumor and bone-related events in patients with multiple myeloma.